Yet another report’s pointing out biotech’s bullish venture appeal – and how medical device investment continues to flag.
In fact, biotechnology funding for human therapeutics is so strong that its venture funding outpaces pharmaceuticals sevenfold, a PricewaterhouseCoopers venture analysis of the first quarter of 2015 life sciences sector found.
It reported 193 deals worth a cumulative $2.2 billion. This is up from a total 186 life sciences deals in the Q1 2014, which were worth $1.6 billion.
Image: http://medcitynews.com
